<p>The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.</p>.<p>Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, according to the company.</p>.Indian-origin Singaporean jailed for coughing at colleagues while he was Covid-infected.<p>Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil. </p>
<p>The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.</p>.<p>Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, according to the company.</p>.Indian-origin Singaporean jailed for coughing at colleagues while he was Covid-infected.<p>Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil. </p>